By Ned Swanson, MD
President and Chief Medical Officer, PolarityBio
I've mentioned the five-year mortality rate for diabetic foot ulcers a few times on our page, and I think it's worth digging into a bit more. We usually talk about these wounds in the language of wound care: healing rates, closure, recurrence. We rarely talk about them the way we talk about serious systemic disease, in terms of survival at five years. But that's the honest frame. By the numbers, a diabetic foot ulcer carries a five-year mortality in the same range as cancer, and a major amputation carries one that's worse than most cancers.
The Numbers
Here's how the comparison looks. Pooled mortality at five years across all cancers is about 31%. For a person with a diabetic foot ulcer, mortality at five years is about 30%, essentially the same [1]. It climbs from there with the severity of the foot disease: roughly 46% after a minor amputation and about 57% after a major one in pooled data, with some series reporting mortality after a major amputation above 70% [2]. For reference, mortality at five years is about 9% for breast cancer and about 80% for lung cancer [1]. A major lower limb amputation, in other words, sits closer to lung cancer than to the cancers most people think of as survivable.
A person with a diabetic foot ulcer has a five-year mortality about equal to the average cancer.
“Toe and Flow,” and the Evidence That Early Intervention Matters
The “toe and flow” model formalizes the teamwork organization around the multidisciplinary care of patients with diabetic foot ulcers to accelerate access to care: defined referral pathways, shared algorithms, and rapid access so that an at-risk foot is seen in days rather than weeks [3].
The outcome data are about as consistent as wound care evidence gets. A 2020 systematic review of 33 studies comparing multidisciplinary diabetic foot care with standard care found that 94%, or 31 of the 33, reported a reduction in major amputations after a coordinated team was established [4]. Regional implementations of the toe and flow model have reported amputation reductions on the order of 39% to 56% [5-7].
The intervention was the coordination that created seamless access and earlier intervention.
So Why Do We Wait?
If a diagnosis carried a 30% five-year mortality in oncology, no one would accept a wait-and-see approach. Yet that's close to how we manage many diabetic foot ulcers. The usual pathway is to start with standard care and reassess at four weeks. If the wound hasn't shrunk by about half by then, it's unlikely to heal on its current course, and only then do we typically escalate to advanced therapies [5]. Coverage criteria for many advanced treatments are built around that same four-week window.
The question I keep coming back to is whether bringing advanced care in earlier could change the long-term picture: faster closure, fewer infections, fewer amputations, and ultimately better survival. Every week a wound stays open is another week of exposure to infection and further tissue loss, and the path from ulcer to amputation rarely happens all at once. If the downstream mortality looks like cancer, it seems fair to ask whether the upstream treatment should look more like early cancer care: identify the risk early, act decisively, and don't wait for the disease to declare itself. Shouldn’t we be taking our lead from “toe and flow,” which has shown that early intervention can improve outcomes?
This isn't about abandoning good standard care. Offloading, debridement, infection control, and vascular assessment remain the foundation. It's about asking whether a four-week waiting period is the right default for a condition this serious, and what the evidence would need to show for us to move sooner.
I believe it’s possible for us to determine the prognosis of a patient with a new ulcer the first day they walk in the door without waiting four weeks. A combination of patient and wound specific factors may be able to inform us if a patient will succeed with standard care or if they need advanced care immediately. We’re working with experts in the field to create just such a staging system. A patient with a diabetic foot ulcer should receive all the same guidance that a patient with cancer receives up front, including prognosis and treatment pathways. It will never be black and white, but our goal is to continually narrow the gray zone and to move predictive information into the picture.
One more finding is worth sitting with. Surveyed patients with diabetic foot disease have reported fearing a major lower limb amputation more than death [4]. Whatever else the statistics say, that is the stake as patients themselves experience it.
A diabetic foot ulcer deserves the same seriousness, and the same instinct to intervene early, that we already bring to the diagnoses we know to fear.
References
1. Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020;13(1):16.
2. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care. 2023;46(1):209-221.
3. Rogers LC, Andros G, Caporusso J, Harkless LB, Mills JL Sr, Armstrong DG. Toe and flow: essential components and structure of the amputation prevention team. J Vasc Surg. 2010;52(3 Suppl):23S-27S.
4. Musuuza J, Sutherland BL, Kurter S, Balasubramanian P, Bartels CM, Brennan MB. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. J Vasc Surg. 2020;71(4):1433-1446.e3.
5. Blanchette V, Brousseau-Foley M, Cloutier L. Effect of contact with podiatry in a team approach context on diabetic foot ulcer and lower extremity amputation: systematic review and meta-analysis. J Foot Ankle Res. 2020;13(1):15.
6. Albright RH, Manohar NB, Murillo JF, Kengne LAM, Delgado-Hurtado JJ, Diamond ML, Acciani AL, Fleischer AE. Effectiveness of multidisciplinary care teams in reducing major amputation rate in adults with diabetes: A systematic review & meta-analysis. Diabetes Res Clin Pract. 2020;161:107996.
7. Basiri R, Haverstock BD, Petrasek PF, Manji K. Reduction in Diabetes-Related Major Amputation Rates After Implementation of a Multidisciplinary Model: An Evaluation in Alberta, Canada. J Am Podiatr Med Assoc. 2021;111(4):Article_1.
8. Wukich DK, Raspovic KM, Suder NC. Patients With Diabetic Foot Disease Fear Major Lower-Extremity Amputation More Than Death. Foot Ankle Spec. 2018 Feb;11(1):17-21. doi: 10.1177/1938640017694722. Epub 2017 Feb 1. PMID: 28817962.